ROIV vs. BBIO

Last updated Apr 2, 2026

Compare and contrast key facts about Roivant Sciences Ltd. (ROIV) and BridgeBio Pharma, Inc. (BBIO).

Performance

ROIV vs. BBIO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Roivant Sciences Ltd. (ROIV) and BridgeBio Pharma, Inc. (BBIO). The values are adjusted to include any dividend payments, if applicable.

ROIV vs. BBIO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
ROIV Roivant Sciences Ltd.	28.29%	83.43%	5.34%	40.55%	-20.73%	7.81%
BBIO BridgeBio Pharma, Inc.	-2.67%	178.75%	-32.03%	429.79%	-54.32%	-65.06%

Fundamentals

Market Cap ROIV : $19.40T BBIO : $14.26B
EPS ROIV : -$0.00 BBIO : -$3.80
PS Ratio ROIV : 486.81K BBIO : 39.21
Total Revenue (TTM) ROIV : $13.31M BBIO : $362.37M
Gross Profit (TTM) ROIV : $12.14M BBIO : $357.09M
EBITDA (TTM) ROIV : -$1.06B BBIO : -$581.79M

Returns By Period

In the year-to-date period, ROIV achieves a 28.29% return, which is significantly higher than BBIO's -2.67% return.

ROIV

• 1D: 0.51%
• 1M: -0.93%
• YTD: 28.29%
• 6M: 76.76%
• 1Y: 182.64%
• 3Y*: 55.67%
• 5Y*: —
• 10Y*: —

BBIO

• 1D: 0.26%
• 1M: 13.66%
• YTD: -2.67%
• 6M: 39.21%
• 1Y: 125.47%
• 3Y*: 64.98%
• 5Y*: 4.63%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ROIV vs. BBIO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ROIV

ROIV Risk / Return Rank: 99
ROIV Sharpe Ratio Rank: 99
ROIV Sortino Ratio Rank: 99
ROIV Omega Ratio Rank: 98
ROIV Calmar Ratio Rank: 99
ROIV Martin Ratio Rank: 99

BBIO

BBIO Risk / Return Rank: 93
BBIO Sharpe Ratio Rank: 94
BBIO Sortino Ratio Rank: 92
BBIO Omega Ratio Rank: 91
BBIO Calmar Ratio Rank: 95
BBIO Martin Ratio Rank: 95

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ROIV vs. BBIO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Roivant Sciences Ltd. (ROIV) and BridgeBio Pharma, Inc. (BBIO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ROIV	BBIO	Difference
Sharpe ratio Return per unit of total volatility	4.56	2.60	+1.96
Sortino ratio Return per unit of downside risk	5.99	3.13	+2.86
Omega ratio Gain probability vs. loss probability	1.71	1.43	+0.28
Calmar ratio Return relative to maximum drawdown	15.69	5.70	+9.99
Martin ratio Return relative to average drawdown	45.97	16.74	+29.23
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ROIV vs. BBIO - Sharpe Ratio Comparison

The current ROIV Sharpe Ratio is 4.56, which is higher than the BBIO Sharpe Ratio of 2.60. The chart below compares the historical Sharpe Ratios of ROIV and BBIO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ROIV	BBIO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	4.56	2.60	+1.96
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.05	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.45	0.19	+0.26

Correlation

The correlation between ROIV and BBIO is 0.37, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ROIV vs. BBIO - Dividend Comparison

Neither ROIV nor BBIO has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ROIV vs. BBIO - Drawdown Comparison

The maximum ROIV drawdown since its inception was -79.22%, smaller than the maximum BBIO drawdown of -92.80%. Use the drawdown chart below to compare losses from any high point for ROIV and BBIO.

Drawdown Indicators

	ROIV	BBIO	Difference
Max Drawdown Largest peak-to-trough decline	-79.22%	-92.80%	+13.58%
Max Drawdown (1Y) Largest decline over 1 year	-11.21%	-20.25%	+9.04%
Max Drawdown (5Y) Largest decline over 5 years	—	-91.89%	—
Current Drawdown Current decline from peak	-6.33%	-6.83%	+0.50%
Average Drawdown Average peak-to-trough decline	-28.38%	-46.72%	+18.34%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.83%	6.89%	-3.06%

Volatility

ROIV vs. BBIO - Volatility Comparison

The current volatility for Roivant Sciences Ltd. (ROIV) is 11.36%, while BridgeBio Pharma, Inc. (BBIO) has a volatility of 17.78%. This indicates that ROIV experiences smaller price fluctuations and is considered to be less risky than BBIO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ROIV	BBIO	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.36%	17.78%	-6.42%
Volatility (6M) Calculated over the trailing 6-month period	30.62%	37.12%	-6.50%
Volatility (1Y) Calculated over the trailing 1-year period	40.41%	48.71%	-8.30%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	61.13%	86.05%	-24.92%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	61.13%	84.69%	-23.56%

Financials